TP53 status and impact on AML prognosis within the ELN 2022 risk classification
- Author(s)
- Fleming, S; Tsai, XC; Morris, R; Hou, HA; Wei, AH;
- Details
- Publication Year 2023-12-07,Volume 142,Issue #23,Page 2029-2033
- Journal Title
- Blood
- Publication Type
- Research article
- Abstract
- This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of -7, -5/del(5q), -17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.
- Publisher
- American Society of Hematology
- Keywords
- Humans; *Leukemia, Myeloid, Acute/genetics; Mutation; Abnormal Karyotype; *Myelodysplastic Syndromes/genetics; Prognosis; Tumor Suppressor Protein p53/genetics
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1182/blood.2023020855
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2023020855- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-16 04:29:35
Last Modified: 2024-01-16 04:53:14